{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:17:11Z","timestamp":1787026631940,"version":"build-2736575974"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The outbreak of coronavirus disease 19 (COVID-19) has highlighted the demand for vaccines that are safe and effective in inducing systemic and airway mucosal immunity against the aerosol transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In this study, we developed a novel helper-dependent adenoviral vector-based COVID-19 mucosal vaccine encoding a full-length SARS-CoV-2 spike protein (HD-Ad-FS). Through intranasal immunization (single-dose and prime-boost regimens), we demonstrated that the HD-Ad-FS was immunogenic and elicited potent systemic and airway mucosal protection in BALB\/c mice, transgenic ACE2 (hACE2) mice, and hamsters. We detected high titers of neutralizing antibodies (NAbs) in sera and bronchoalveolar lavages (BALs) in the vaccinated animals. High levels of spike-specific secretory IgA (sIgA) and IgG were induced in the airway of the vaccinated animals. The single-dose HD-Ad-FS elicited a strong immune response and protected animals from SARS-CoV-2 infection. In addition, the prime-boost vaccination induced cross-reactive serum NAbs against variants of concern (VOCs; Beta, Delta, and Omicron). After challenge, VOC infectious viral particles were at undetectable or minimal levels in the lower airway. Our findings highlight the potential of airway delivery of HD-Ad-FS as a safe and effective vaccine platform for generating mucosal protection against SARS-CoV-2 and its VOCs.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1430928","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T01:03:16Z","timestamp":1724979796000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Intranasal HD-Ad-FS vaccine induces systemic and airway mucosal immunities against SARS-CoV-2 and systemic immunity against SARS-CoV-2 variants in mice and hamsters"],"prefix":"10.3389","volume":"15","author":[{"given":"Peter","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Watt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juntao","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huibi","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongqi","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Claude","family":"Gingras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Rini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2004973","article-title":"Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1","volume":"382","author":"Van Doremalen","year":"2020","journal-title":"New Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2015482118","article-title":"Mechanistic transmission modeling of COVID-19 on the Diamond Princess cruise ship demonstrates the importance of aerosol transmission","volume":"118","author":"Azimi","year":"2021","journal-title":"Proc Natl Acad Sci"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses","volume":"586","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"New Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and efficacy of NVX-CoV2373 Covid-19 vaccine","volume":"385","author":"Heath","year":"2021","journal-title":"New Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01429-X","article-title":"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey","volume":"398","author":"Tanriover","year":"2021","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.61312","article-title":"Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants","volume":"9","author":"Weisblum","year":"2020","journal-title":"elife"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2104974","article-title":"Effectiveness of the BNT162b2 covid-19 vaccine against the B. 1.1. 7 and B. 1.351 variants","volume":"385","author":"Abu-Raddad","year":"2021","journal-title":"New Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00432-3","article-title":"Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.add4853","article-title":"Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination","volume":"7","author":"Tang","year":"2022","journal-title":"Sci Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e181514","DOI":"10.1001\/jamapediatrics.2018.1514","article-title":"Effectiveness of live attenuated vs inactivated influenza vaccines in children during the 2012-2013 through 2015-2016 influenza seasons in Alberta, Canada: a Canadian Immunization Research Network (CIRN) study","volume":"172","author":"Buchan","year":"2018","journal-title":"JAMA Pediatr"},{"key":"B13","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41541-022-00493-x","article-title":"Intranasal immunization with avian paramyxovirus type 3 expressing SARS-CoV-2 spike protein protects hamsters against SARS-CoV-2","volume":"7","author":"Park","year":"2022","journal-title":"NPJ Vaccines"},{"key":"B14","doi-asserted-by":"publisher","first-page":"4811","DOI":"10.1016\/j.cell.2022.11.006","article-title":"Intranasal pediatric parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in monkeys","volume":"185","author":"Le Nou\u00ebn","year":"2022","journal-title":"Cell"},{"key":"B15","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.cell.2020.08.026","article-title":"A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2","volume":"183","author":"Hassan","year":"2020","journal-title":"Cell"},{"key":"B16","unstructured":"Draft landscape of COVID-19 candidate vaccines2023"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S1525-0016(03)00059-5","article-title":"Reduced inflammation and improved airway expression using helper-dependent adenoviral vectors with a K18 promoter","volume":"7","author":"Toietta","year":"2003","journal-title":"Mol Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.11.5966-5972.2004","article-title":"Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo","volume":"78","author":"Muruve","year":"2004","journal-title":"J Virol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1089\/hum.2015.108","article-title":"Long-term expression of the human cftr gene in mouse airway via helper-dependent adenoviral vector delivery and transient immunosuppression","volume":"27","author":"Cao","year":"2016","journal-title":"Hum Gene Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1606050113","article-title":"Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination","volume":"113","author":"Tam","year":"2016","journal-title":"Proc Natl Acad Sci"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1038\/mtna.2013.55","article-title":"Efficient gene delivery to pig airway epithelia and submucosal glands using helper-dependent adenoviral vectors","volume":"2","author":"Cao","year":"2013","journal-title":"Mol Therapy-Nucleic Acids"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/dth.2011.24.issue-5","article-title":"Biopump: Autologous skin-derived micro-organ genetically engineered to provide sustained continuous secretion of therapeutic proteins","volume":"24","author":"Mitrani","year":"2011","journal-title":"Dermatol Ther"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13578-021-00723-0","article-title":"Intranasal HD-Ad vaccine protects the upper and lower respiratory tracts of hACE2 mice against SARS-CoV-2","volume":"11","author":"Cao","year":"2021","journal-title":"Cell Biosci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abc3539","article-title":"Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits","volume":"12","author":"Ravichandran","year":"2020","journal-title":"Sci Trans Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01318-5","article-title":"Sensitivity of infectious SARS-CoV-2 B. 1.1. 7 and B. 1.351 variants to neutralizing antibodies","volume":"27","author":"Planas","year":"2021","journal-title":"Nat Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03777-9","article-title":"Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization","volume":"596","author":"Planas","year":"2021","journal-title":"Nature"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04389-z","article-title":"Considerable escape of SARS-CoV-2 Omicron to antibody neutralization","volume":"602","author":"Planas","year":"2022","journal-title":"Nature"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2312-y","article-title":"The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice","volume":"583","author":"Bao","year":"2020","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01753-y","article-title":"Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants","volume":"28","author":"Tseng","year":"2022","journal-title":"Nat Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108891","article-title":"Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant","volume":"385","author":"Lopez Bernal","year":"2021","journal-title":"New Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2009799117","article-title":"Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development","volume":"117","author":"Imai","year":"2020","journal-title":"Proc Natl Acad Sci"},{"key":"B33","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41590-018-0260-6","article-title":"The establishment of resident memory B cells in the lung requires local antigen encounter","volume":"20","author":"Allie","year":"2019","journal-title":"Nat Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"109400","DOI":"10.1016\/j.celrep.2021.109400","article-title":"A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters","volume":"36","author":"Bricker","year":"2021","journal-title":"Cell Rep"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109452","article-title":"An intranasal vaccine durably protects against SARS-CoV-2 variants in mice","volume":"36","author":"Hassan","year":"2021","journal-title":"Cell Rep"},{"key":"B36","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s41392-023-01423-6","article-title":"Intranasal booster using an Omicron vaccine confers broad mucosal and systemic immunity against SARS-CoV-2 variants","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduction Targeted Ther"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.20173","article-title":"Secretory IgA antibodies provide cross-protection against infection with different strains of influenza B virus","volume":"74","author":"Asahi-Ozaki","year":"2004","journal-title":"J Med Virol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2209651","article-title":"Anti-spike mucosal IgA protection against SARS-CoV-2 omicron infection","volume":"387","author":"Havervall","year":"2022","journal-title":"New Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2213153","article-title":"Mucosal igA against SARS-coV-2 omicron infection","volume":"387","author":"Zuo","year":"2022","journal-title":"New Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"103788","DOI":"10.1016\/j.ebiom.2021.103788","article-title":"Mucosal immune response in BNT162b2 COVID-19 vaccine recipients","volume":"75","author":"Azzi","year":"2022","journal-title":"EBioMedicine"},{"key":"B41","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.cell.2022.01.015","article-title":"SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron","volume":"185","author":"Tarke","year":"2022","journal-title":"Cell"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.142032","article-title":"Human angiotensin-converting enzyme 2 transgenic mice infected with SARS-CoV-2 develop severe and fatal respiratory disease","volume":"5","author":"Golden","year":"2020","journal-title":"JCI Insight"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1601896","article-title":"Sex-based differences in susceptibility to severe acute respiratory syndrome coronavirus infection","volume":"198","author":"Channappanavar","year":"2017","journal-title":"J Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","article-title":"OpenSAFELY: factors associated with COVID-19 death in 17 million patients","volume":"584","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2700-3","article-title":"Sex differences in immune responses that underlie COVID-19 disease outcomes","volume":"588","author":"Takahashi","year":"2020","journal-title":"Nature"},{"key":"B46","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.medj.2022.03.004","article-title":"Reduced pathogenicity of the SARS-CoV-2 omicron variant in hamsters","volume":"3","author":"McMahan","year":"2022","journal-title":"Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04441-6","article-title":"SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters","volume":"603","author":"Halfmann","year":"2022","journal-title":"Nature"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1126\/science.abn8939","article-title":"Pathogenicity, transmissibility, and fitness of SARS-CoV-2 Omicron in Syrian hamsters","volume":"377","author":"Yuan","year":"2022","journal-title":"Science"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00396-0","article-title":"Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial","volume":"21","author":"Wu","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B50","doi-asserted-by":"publisher","first-page":"104298","DOI":"10.1016\/j.ebiom.2022.104298","article-title":"Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial","volume":"85","author":"Madhavan","year":"2022","journal-title":"EBioMedicine"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02753-7","article-title":"Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial","volume":"399","author":"Halperin","year":"2022","journal-title":"Lancet"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"B53","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41541-023-00717-8","article-title":"Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin\u00ae)","volume":"8","author":"Singh","year":"2023","journal-title":"NPJ Vaccines"},{"key":"B54","doi-asserted-by":"publisher","first-page":"R7","DOI":"10.1093\/hmg\/ddr143","article-title":"Helper-dependent adenoviral vectors for liver-directed gene therapy","volume":"20","author":"Brunetti-Pierri","year":"2011","journal-title":"Hum Mol Genet"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00223.2021","article-title":"The SARS-CoV-2 spike protein subunit S1 induces COVID-19-like acute lung injury in K18-hACE2 transgenic mice and barrier dysfunction in human endothelial cells","volume":"321","author":"Biancatelli","year":"2021","journal-title":"Am J Physiology-Lung Cell Mol Physiol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.121.318902","article-title":"SARS-CoV-2 spike protein impairs endothelial function via downregulation of ACE 2","volume":"128","author":"Lei","year":"2021","journal-title":"Circ Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abl9105","article-title":"SARS-CoV-2 infection generates tissue-localized immunological memory in humans","volume":"6","author":"Poon","year":"2021","journal-title":"Sci Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2010.125","article-title":"Readministration of helper-dependent adenoviral vectors to mouse airway mediated via transient immunosuppression","volume":"18","author":"Cao","year":"2011","journal-title":"Gene Ther"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00122-6","article-title":"Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study","volume":"23","author":"Arbel","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2215471","article-title":"Effectiveness of bivalent boosters against severe omicron infection","volume":"388","author":"Lin","year":"2023","journal-title":"New Engl J Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abq3059","article-title":"SARS-CoV-2 infection in hamsters and humans results in lasting and unique systemic perturbations after recovery","volume":"14","author":"Frere","year":"2022","journal-title":"Sci Trans Med"},{"key":"B62","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/978-1-59745-237-3_3","article-title":"Methods for the production of helper-dependent adenoviral vectors","volume":"1","author":"Doux","year":"2008","journal-title":"Gene Ther Protocols: Production In Vivo Appl Gene Transfer Vectors"},{"key":"B63","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/B978-012465330-6\/50003-8","article-title":"Virus isolation and quantitation","volume-title":"Virology methods manual","author":"Hierholzer","year":"1996"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1430928\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T01:03:20Z","timestamp":1724979800000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1430928\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,30]]},"references-count":63,"alternative-id":["10.3389\/fimmu.2024.1430928"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1430928","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,30]]},"article-number":"1430928"}}